Indaptus Therapeutics, INC Form 4 insider transactions

Indaptus Therapeutics Director David E. Lazar sold a substantial portion of his Series AA and Series AAA Preferred Stock holdings, convertible into millions of common shares.

Indaptus Therapeutics Director Jerome Jabbour was granted 25,000 stock options as part of the company's non-employee director compensation program.

Indaptus Therapeutics Director Avraham Ben-Tzvi acquired 25,000 shares of restricted common stock and 25,000 stock options as part of compensation.

Indaptus Therapeutics Director David Natan was granted options to purchase 25,000 shares of common stock as part of the company's non-employee director compensation program.

Indaptus Therapeutics' Chief Financial Officer, Nir Sassi, acquired 26,758 shares of common stock at $2.03 per share on December 22, 2025, as part of an employment agreement amendment.

Indaptus Therapeutics Co-Chief Executive Officer Jeffrey Meckler acquired 216,617 shares of common stock at $2.03 per share, increasing his total beneficial ownership to 229,929 shares.

Indaptus Therapeutics' CSO and Director, Michael Newman, acquired 52,204 shares of common stock at $2.03 per share.

Indaptus Therapeutics' Chief Operating Officer, Walt Linscott, acquired 54,421 shares of common stock at $2.03 per share, increasing his direct beneficial ownership.

Indaptus Therapeutics CEO Jeffrey Meckler acquired 6,068 shares of common stock and 12,136 warrants through the mandatory conversion of a convertible note at a discounted price of $8.3024 per share, following a 1-for-28 reverse stock split.

Indaptus Therapeutics, Inc. Director Hila Karah was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Indaptus Therapeutics, Inc. Director Robert Martell was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026, as disclosed in a recent SEC Form 4 filing.

Indaptus Therapeutics, Inc. Director William B. Hayes was granted 12,500 stock options with an exercise price of $0.33, which will vest in June 2026.

Indaptus Therapeutics, Inc. Director Anthony J. Maddaluna was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Indaptus Therapeutics, Inc. Director and 10% Owner Roger Pomerantz was granted 30,000 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Indaptus Therapeutics, Inc. Director Mark John Gilbert was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Nir Sassi, CFO of Indaptus Therapeutics, disposed of several stock option holdings on April 10, 2025, through a mutual agreement with the company.

Walt Addison Linscott, Chief Operating Officer of Indaptus Therapeutics, Inc., canceled several stock option grants by mutual agreement, receiving $500 in consideration.

Roger Pomerantz, a director at Indaptus Therapeutics, canceled stock options by mutual agreement with the company, receiving $500 in consideration.

CEO Jeffrey Meckler reports the cancellation of several stock option grants by mutual agreement with Indaptus Therapeutics, receiving $500 in consideration.

Director Anthony Maddaluna cancels stock options in Indaptus Therapeutics, receiving $500 in consideration.

Director Hila Karah cancels multiple stock option grants in Indaptus Therapeutics, receiving $500 in consideration.

Director William B Hayes cancels stock options in Indaptus Therapeutics, receiving $500 in consideration.

Indaptus Therapeutics CEO, Jeffrey Meckler, acquired 42,553 shares of common stock and 42,553 warrants at a price of $1.175 per share and $1.05 per warrant respectively.

Michael Newman, CSO and Director of Indaptus Therapeutics, acquired 75,000 stock options on October 9, 2024.

Nir Sassi, CFO of Indaptus Therapeutics, acquired 75,000 stock options on October 9, 2024, according to a Form 4 filing with the SEC.

Roger J. Waltzman, Chief Medical Officer of Indaptus Therapeutics, acquired 75,000 stock options on October 9, 2024.

Walt Addison Linscott, Chief Operating Officer of Indaptus Therapeutics, Inc., acquired stock options for 75,000 shares on October 9, 2024.

Jeffrey Meckler, CEO of Indaptus Therapeutics, receives stock options for 75,000 shares.

Indaptus Therapeutics CEO Jeffrey Meckler acquired 84,932 shares of common stock and an equal number of warrants at a price of $1.825 per share on August 8, 2024.

Director Hila Karah acquired stock options for 12,500 shares of Indaptus Therapeutics common stock on June 6, 2024.